« Return to News | Awards & Advancement

Sangart appoints three to leadership team

Friday, February 17, 2012 12:43 PM

Sangart, a privately held biopharmaceutical company focused on oxygen-therapeutic agents, has appointed three new members to its executive team.

Frank Booth, MA, MSc, BM, BCh, FACS, was appointed to chief medical officer. Booth has more than 20 years of experience as a trauma and critical care surgeon and as a clinical investigator. Previously he worked in clinical development roles at Novo Nordisk and Eli Lilly.

Mary Rose Keller was appointed vice president of clinical operations, responsible for the execution of all clinical programs, including sickle cell, trauma and future treatments at Sangart. She has more than 25 years of experience in clinical research and trial execution and has been involved with numerous, successful regulatory submissions for companies such as Agouron, Pfizer and Shire Pharmaceuticals.

Carmen Betancourt-Riche, MBA, was appointed vice president of regulatory affairs and quality assurance, overseeing the design and execution of Sangart's global regulatory and quality assurance strategy. She more than 34 years of drug development experience in the pharmaceutical industry and has held senior regulatory roles at BioMarin Pharmaceutical, Cerexa, Coulter Pharmaceuticals, Genentech, KaloBios Pharmaceuticals and VaxGen.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.